Compare Torrent Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ASTRAZENECA PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ASTRAZENECA PHARMA TORRENT PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 38.5 127.0 30.3% View Chart
P/BV x 9.8 38.9 25.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 TORRENT PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
TORRENT PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,9641,278 153.7%   
Low Rs1,245883 141.1%   
Sales per share (Unadj.) Rs453.4228.4 198.5%  
Earnings per share (Unadj.) Rs25.810.4 248.8%  
Cash flow per share (Unadj.) Rs62.316.3 383.1%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs279.298.8 282.7%  
Shares outstanding (eoy) m169.2225.00 676.9%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.54.7 74.8%   
Avg P/E ratio x62.2104.2 59.7%  
P/CF ratio (eoy) x25.866.4 38.8%  
Price / Book Value ratio x5.710.9 52.5%  
Dividend payout %65.90-   
Avg Mkt Cap Rs m271,51327,008 1,005.3%   
No. of employees `00013.61.4 1,002.8%   
Total wages/salary Rs m14,0381,535 914.3%   
Avg. sales/employee Rs Th5,642.64,210.9 134.0%   
Avg. wages/employee Rs Th1,032.41,132.2 91.2%   
Avg. net profit/employee Rs Th320.9191.1 167.9%   
INCOME DATA
Net Sales Rs m76,7285,710 1,343.7%  
Other income Rs m571123 465.7%   
Total revenues Rs m77,2995,833 1,325.3%   
Gross profit Rs m19,831463 4,284.0%  
Depreciation Rs m6,177147 4,190.6%   
Interest Rs m5,0380-   
Profit before tax Rs m9,187438 2,097.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,254179 700.7%   
Profit after tax Rs m4,363259 1,683.9%  
Gross profit margin %25.88.1 318.8%  
Effective tax rate %13.640.8 33.4%   
Net profit margin %5.74.5 125.3%  
BALANCE SHEET DATA
Current assets Rs m50,3753,209 1,569.7%   
Current liabilities Rs m51,6532,070 2,495.9%   
Net working cap to sales %-1.720.0 -8.3%  
Current ratio x1.01.6 62.9%  
Inventory Days Days9272 127.3%  
Debtors Days Days6835 195.6%  
Net fixed assets Rs m83,648790 10,584.4%   
Share capital Rs m84650 1,692.4%   
"Free" reserves Rs m46,3972,419 1,917.8%   
Net worth Rs m47,2442,469 1,913.2%   
Long term debt Rs m39,1290-   
Total assets Rs m141,2094,605 3,066.2%  
Interest coverage x2.8NM-  
Debt to equity ratio x0.80-  
Sales to assets ratio x0.51.2 43.8%   
Return on assets %6.75.6 118.3%  
Return on equity %9.210.5 88.0%  
Return on capital %12.317.7 69.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,103300 7,378.6%   
Fx outflow Rs m5,5222,015 274.0%   
Net fx Rs m16,581-1,715 -966.6%   
CASH FLOW
From Operations Rs m17,98188 20,456.0%  
From Investments Rs m-2,413-94 2,577.8%  
From Financial Activity Rs m-13,145NA-  
Net Cashflow Rs m2,380-6 -41,757.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 15.7 80.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 12,856 206.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT PHARMOVA   DIVIS LABORATORIES  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 14, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS